Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Xentria, Inc. has announced a peer-reviewed publication in Frontiers in Pharmacology, detailing a biosimulation model for its treatment candidate, XTMAB-16, aimed at pulmonary sarcoidosis. Partnering with Certara, Inc., the model aids in estimating safe and effective dosing for upcoming clinical trials slated for early 2023. XTMAB-16, an anti-TNF monoclonal antibody, has shown promise in reducing granuloma formation. The publication represents a significant collaboration in sarcoidosis research, potentially marking the first use of an in vitro model to guide dosing in clinical trials. Xentria aims to launch its first patient trial soon.
Certara has announced the integration of deep learning capabilities into its scientific informatics software platform, D360. This enhancement aims to improve data-driven decision-making in drug discovery by allowing users to predict properties of chemical structures and access unstructured data. The new features include Automated Property Prediction, Novel Structure Generation, and enhanced access to literature-based insights. Certara acquired these advanced capabilities from Vyasa and will showcase them at the Lab of the Future Congress in Boston.
Certara, Inc. (CERT) announced the launch of Simcyp Simulator Version 22, enhancing its capabilities for drug development. This advanced platform has been utilized to support over 300 label claims for more than 90 FDA-approved novel drugs, allowing for comprehensive analysis without human clinical trials. Key upgrades include enhanced subcutaneous dosing predictions, expanded compound libraries, and additional ethnic populations for improved therapeutic applications. Certara aims to facilitate faster medicine delivery through its continuing commitment to advanced biosimulation technologies.
Certara, a leader in biosimulation, reported a strong financial performance for Q4 and full-year 2022. Q4 revenue grew by 15% to $86.6 million, with net income of $9.2 million, reversing a loss from the previous year. For the full year, revenue reached $335.6 million, up 17%, with a net income of $14.7 million. Adjusted EBITDA also saw an increase, totaling $31.9 million for Q4 and $120.2 million for the year. Looking ahead, Certara projects 2023 revenues between $370 million and $385 million, with adjusted EBITDA expectations of $131 million to $137 million. The acquisition of Vyasa Analytics is positioned to strengthen its market position.
Certara, Inc. (Nasdaq: CERT) announced that John Gallagher will replace Andrew Schemick as Chief Financial Officer effective April 1, 2023. Gallagher brings nearly 25 years of experience, including his recent role as CFO of Cue Health and various positions at Becton Dickinson. Schemick transitions to Senior Vice President of Corporate Operations, focusing on operational excellence during Certara's growth. CEO William Feehery expressed excitement about Gallagher’s expertise to drive growth and thanked Schemick for his leadership over the past nine years, which included an IPO and significant capitalizations.
Certara (Nasdaq: CERT) announced its participation in the Barclays Global Healthcare Conference on March 15, 2023, at 11:15 AM ET. This event highlights the company's leadership in biosimulation technology aimed at transforming drug discovery and development. A live webcast will be hosted on Certara’s investor relations website, with a replay available for 90 days. Certara serves over 2,000 clients, including biopharmaceutical companies and regulatory agencies across 62 countries. The company continues to accelerate medicine development through its proprietary software and services.
Certara, Inc. (Nasdaq: CERT), renowned for its biosimulation expertise, has announced it will disclose its financial results for the fourth quarter and full year of 2022 post-market on March 1, 2023. The company will host a conference call at 5:00 p.m. ET to discuss these results. Interested investors can register in advance to listen live, with an archive available afterward. Certara provides innovative biosimulation software and services to a global clientele that includes over 2,000 biopharmaceutical firms, academic institutions, and regulatory bodies.
Certara has announced the acquisition of Vyasa Analytics, enhancing its software capabilities with advanced deep-learning technology aimed at the life sciences sector. This acquisition will integrate Vyasa's AI-driven solutions, including the LAYAR data platform, into Certara's biosimulation software, broadening its product offerings and improving decision-making in drug development. Certara serves over 2,000 clients globally, leveraging proprietary software to accelerate drug discovery and development.
Certara, Inc. (Nasdaq: CERT) has completed a $449 million stock purchase from funds controlled by EQT Private Equity, marking a significant investment by Arsenal Capital Partners. As part of this deal, David Spaight, an Operating Partner at Arsenal, has been appointed to Certara’s Board of Directors. Arsenal has committed to a two-year lock-up period, reflecting its long-term commitment as a shareholder. Spaight's extensive experience in the biopharmaceutical sector is expected to enhance Certara’s strategic direction and growth prospects.
Certara, Inc. (Nasdaq: CERT) reported significant growth for Q3 2022, achieving $84.7 million in revenue, a 15% increase year-over-year. This growth was complemented by a net income of $3.9 million, a notable turnaround from a net loss of $1.8 million in the same quarter last year. Adjusted EBITDA rose 25% to $32.7 million. The company reiterated its full-year revenue guidance of $325 million to $335 million. Additionally, Arsenal Investment Partners is set to acquire 30 million shares at $15 per share, strengthening shareholder support.